Soluble CD23 (sCD23) has multiple IgE-independent biological activities. In the present study, we examined the regulatory effect of sCD23 on cytokine production by human peripheral blood mononuclear cells (PBMC). We show that sCD23 enhances by about 80-fold the interleukin 2 (IL-2)-induced interferon 7 (IFN-3') production and by about 10-fold the response to IL-12. This potentiating activity is time and dose dependent and is not associated with a significant effect on DNA synthesis. The sCD23 costimulatory activity for IFN-3' synthesis is drastically reduced in monocyte-depleted PBMC, suggesting that monocytes may be the target for sCD23, This hypothesis was supported by the following observations. First, sCD23 alone is a potent inducer of tumor necrosis factor a (TNF-ot) production by PBMC and this effect disappears after monocyte depletion. The triggering of TNF-ot release is specifically inhibited by neutralizing anti-CD23 monoclonal antibody (mAb). In addition, IL-2 and IL-12 synergize with sCD23 to induce TNF-ot production. Second, sCD23 triggers the release of other inflammatory mediators such as IL-lot, IL-1/3, and IL-6. Finally, TNF-a production in response to IL-2 and sCD23 precedes IFN-y and IFN-3' secretion is significantly inhibited by anti-TNF-c~ mAb, indicating that the sCD23 costimulatory signal for IFN-y production may be partially mediated by TNF-ot release. It is proposed that sCD23 is a proinflammatory cytokine that, in addition, may play an important role in the control of the immune response via the enhancement of IFN-N production.
T he CD23 antigen (low affinity receptor for IgE) (FceRII) is a 45-kD membrane type II glycoprotein mainly expressed on B lymphocytes and monocytes (1). However, it can also be found on a variety of hematopoietic cells including eosinophils, platelets, and T cells (1). Membrane CD23 is cleaved by autoproteolysis into soluble forms of various molecular sizes (2, 3) . Although CD23 and its soluble products were demonstrated to be involved in IgE regulation (4, 5) , most of the activities ascribed to soluble CD23 are pleiotropic and IgE independent. These include costimulation with IL-1 of prothymocyte maturation (6) , myeloid precursor cell growth (7) , prevention of apoptosis of germinal center B cells (8) , and increase of histamine release by human basophils (9) . The last two activities are shared by some anti-CD21 mAbs (8, 9) , inasmuch as CD21 is reported to be a novel ligand for CD23 (10) .
IL-4 and, more recently, IL-13, are the most potent inducers of CD23 and sCD23 in B cells (11, 12) . In addition to IL-4, both IL-3 and GM-CSF increase CD23 expression and sCD23 release by human monocytes (13) . IFN-y modulates CD23 expression by inhibiting the IL-4-induced CD23 expression on B cells (11) . On monocytes, IFN-3' induces sCD23 release, whereas its effects on surface CD23 expression is still debated (14) (15) (16) . In the studies presented here, we investigated the regulatory activities of soluble CD23 (sCD23) 1 on cytokine production by unfractionated PBMC. We demonstrate that sCD23 costimulates IL-2 or IL-12-induced IFN-3' production and directly triggers TNF-ot, IL-lot, IL-13, and IL-6 release by human PBMC.
Materials and Methods
Reagents. Human recombinant IL-2 was kindly provided by Dr. D. Bron (Institut Bordet, Brussels, Belgium). Human recombinant IL-12 was a generous gift from Dr. M. Gately (HoffmannLa Roche, Nutley, NJ). Affinity-purified recombinant sCD23, mAb to CD23 (clone 63), and class-matched control mAbs were prepared in our laboratory (17, 18) . Neutralizing anti-TNF-o~ mAb was purchased from 1~ & D Systems, Inc. (Minneapolis, MN). All mAbs, cytokines, media, and additives contained low endotoxin levels (<15 pg/ml) as determined by the chromogenic Limulus amebocyte lysate (QCL-1000; BioWhittaker, Inc., Walkersville, MD).
I Abbreviation used in this paper: sCD23, soluble CD23.
Cell Preparation and Culture Conditions. PBMC were isolated by density gradient centrifugation of heparinized blood using Lymphoprep (Nycomed, Oslo, Norway). Monocyte depletion was achieved with anti-CD14 (Becton Dickinson & Co., Mountain View, CA)-coated goat anti-mouse IgG Dynabeads (Dynal, Oslo, Norway). PBMC and monocyte-depleted PBMC were cultured in quadruplicate at 106/ml in 96-well flat-bottomed Falcon plates (Becton Dickinson, Lincoln Park, NJ) in complete serum-free HB101 medium (GIBCO BRL, Gaithersburg, MD) supplemented with 2 mM glutamine, 1 mM sodium pyruvate, 10 mM Hepes, 100 IU penicillin, and 100/~g/ml streptomycin. For proliferation assay, cells were pulsed with 0.5 #Ci [3H]thymidine (Amersham Corp., Arlington Heights, IL) during the last 6 h of the culture period and [3H]thymidine incorporation was measured by a standard liquid scintillation counter. For TNF-c~, IL-I~, IL-1/3, and IL-6 production, cultures were performed at 106/ml in 5-ml sterile Falcon tubes (Becton Dickinson).
Lymphokine Determinations, IFN-7 was measured by two-site solid-phase RIA using anti-IFN-7 mAb (clone 42.25) to coat the solid phase and 125I-labeled anti-IFN-3, mAb (clone KM48, provided by Dr. S. Alkan, Ciba-Geigy, Basel, Switzerland) as detecting probe. The cytokine-specific ELISA and their sensitivities were: IL-lot (3.9 pg/ml), IL-1/3 (3.9 pg/ml), and IL-6 (4.6 pg/ml) (R & D Systems, Inc.). TNF-ot was assessed using a sandwich ELISA employing mouse mAb to human TNF-c~ (clone T144.B, kindly given by Dr. T. Nakajima, St. Mariana University School of Medicine, Kawasaki, Japan) and a polyclonal rabbit anti-TNF-ot antibody received from Dr. J. Tavernier (Roche Research Institute, Ghent, Belgium). The assay was calibrated against the TNF-c~ standard obtained from the National Institute of Biological Standards and Control (Hertfordshire, England). The limit of detection for the TNF-~ ELISA was 150 pg/ml.
Results
sCD23 Enhances IFN-9, Production. To determine the regulatory effects of sCD23 on IFN-3, production, normal human PBMC were stimulated for 3 d with either IL-2 or IL-12 in the presence of sCD23. As shown in Fig. 1 , sCD23 strongly increases by 'x,80-fold the IL-2-induced IFN-3, production and enhances by *10-fold the response to IL-12.
Of note, sCD23 alone is unable to induce IFN-y production. The costimulatory activity of sCD23 is observed at various cytokine concentrations ranging from 25 to 500 U/ml for IL-2 ( Fig. 2) , and from 10 to 60 pM for IL-12 (data not shown) suggesting that sCD23 lowers the threshold for cytokine-induced IFN-y production by PBMC. To further investigate the regulation of IFN-3, production by sCD23, we examined the effect of varying the stimulation period and titrating the concentrations of sCD23. Time course analysis showed that the sCD23 potentiating activity is already observed at day i (mean + SD of three separate experiments: 228 _+ 8 U/ml of IFN-3, in treated vs 8.6 _+ 3.2 U/ml in untreated cultures) reaching plateau at day 5 ( Fig. 3 ). sCD23 costimulates IFN-3' secretion in a dose-dependent manner (Fig. 4) . Its effect is significant at 3 ng/ml whereas optimal enhancement of IFN-3, production is observed at concentrations between 25 and 50 ng/ml (data not shown). These data also indicate that sCD23 has little or no effect on IL-2-or IL-12-induced DNA synthesis strongly suggesting that the increase in IFN-3, production is not related to cell prolifera- (Fig. 5 A) and specific (Fig. 5  B) . Indeed, the TNF-ot production in response to sCD23 alone or sCD23 and IL-2 is completely abolished by neutralizing anti-CD23 mAb with no effect of isotype-matched control mAb (Fig. 5 B) . We next performed kinetic studies and showed that TNF-ot secretion in response to IL-2 and sCD23 precedes IFN-'y production suggesting that the sCD23-induced TNF-ot secretion by monocytes may partially mediate the costimulatory signal for PBMC IFN-3' production (Fig. 6 A) . This hypothesis is supported by the observations that neutralizing anti-TNF-ot mAb significantly decreases PBMC or monocyte-depleted PBMC were cultured in the absence or presence of sCD23 (25 ng/ml), IL-2 (25 U/ml), or IL-2 and sCD23. TNF-ot and IFN-T production were measured in culture supernatants after 20 h and 3 d, respectively.
the IL-2 and sCD23-induced IFN-'y production (Fig. 6 B) .
Finally, we determined whether sCD23 triggers the release of other inflammatory mediators by PBMC. As illustrated in Table 2 
Discussion
In the present study, we first report that sCD23 provides a potent costimulus for PBMC IFN-y production in the presence of IL-2 or IL-12. This potentiating activity is time and dose dependent, and is observed at low IL-2 concentrations. The IFN-3' expression is limited to two normal cell types, T and NK cells (19) . Physiological activation of T lymphocytes to induce cytokine production, including IFN-% requires TCR occupancy and APC-derived costimulatory signals (23) . More precisely, monocytes are reported to enhance IFN-q/ synthesis by mitogen-stimulated T cells via direct cell-cell contact involving CD2 signaling (24) . However, IL-1 (20) or TNF-ot (21) in synergy with IL-2 may partially replace the monocyte-mediated IFN-'y production signal. Similarly, IFN-'y production by stimulated SCID splenocytes (NK cells) required TNF-ot synthesis (22) . In this SCID model, IL-2 was synergistic with IL-12 or IL-12 plus TNF-cz to induce IFN-%' release, but not with TNF-ot alone (25) .
In agreement with the above studies, our results indicate that the enhancement of IFN-y by sCD23 largely depends on the presence of monocytes. Furthermore, we show that sCD23 synergizes with IL-2 and IL-12 to induce TNF-o~ release and that this effect completely disappears upon selective monocyte depletion. Taken together, it is tempting to speculate that the sCD23 costimulatory activity for IFN-'y production is mediated by TNF-ot release and that monocytes are the target for sCD23 and the source of TNF-ot production. This hypothesis is supported by the observations that TNF-c~ production precedes IFN-y secretion and that neutralizing anti-TNF-ot mAb partially inhibits the IL-2-and sCD23-induced IFN-y production. It should be mentioned that NK cells are also capable of producing TNF-ot (26). We next demonstrate that sCD23 is a proinflammatory cytokine inasmuch as sCD23 alone directly triggers TNF-ol, IL-lc~, IL-1B, and IL-6 release by PBMC. The sCD23-induced TNF-o~ occurs rapidly (already detectable after 5 h) and is specific since neutralizing anti-CD23 mAb abolishes sCD23 or IL-2 and sCD23-induced TNF-c~ production. Although monocytes release TNF-a and IL-1 after stimulation with endotoxin, PMA or gram-positive bacterial components, some more physiological triggers have been described such as LFA-3, CD44, and CD45 engagement (27) . Alderson et al. (28) , recently reported that CD40L-transfected cells costimulated TNF-c~ production by purified monocytes in the presence of GM-CSF, IL-3, or IFN-% Finally, ligation of membrane CD23 on IL-4-treated monocytes by anti-CD23 mAb (29) or by IgE-immune complexes (30) triggers inflammatory mediator release, further suggesting that the CD23 Ag may be considered as a proinflammatory molecule. Of note, and in agreement with our previous report (29) , anti-CD23 mAb alone does not trigger inflammatory mediator release in unstimulated monocytes (Fig. 5 B) .
The present observations that the costimulus provided by sCD23 for PBMC IFN-~/and TNF-o~ production disappears after monocyte depletion and that sCD23 alone is a potent inducer of inflammatory mediators strongly suggest that monocytes express a ligand for CD23. In addition to the wellestablished IgE molecule, CD21 has been proposed to serve as a second ligand for CD23 (10) . However, CD21 Ag is primarily expressed on B cells and follicular dendritic cells but not on monocytes (31) . We recently reported (32) that sCD23 binds to a novel ligand different than IgE and CD21. Our unpublished data indicate that monocytes express this sCD23 binding molecule, suggesting without demonstrating, that this novel ligand may be a functional receptor.
Whether the in vivo overexpression of CD23 is involved in the increased levels of inflammatory cytokines seen in certain disease states remains to be determined. For instance, in patients with rheumatoid arthritis, IL-1, TNF-o~, and GM-CSF has been found in synovial fluid (33) . Also, their sera contained elevated levels of serum sCD23 (16 ng/ml in rheumatoid arthritis vs 4.5 ng/ml in control sera) (34) . The possibility therefore exists that GM-CSF, which has been shown to induce CD23 expression on monocytes (13), may be involved in the progression of the disease. In that regard, Hellen et al. (35) , have reported that high CD23 expression in synovial biopsy from patients with all forms of arthritis may be related to the severity of the inflammatory infiltrate. Similarly, in patients suffering of chronic renal failure, increased levels of serum sCD23 were shown to be correlated with TNF-ol and IL-6 (36). We hypothesize that T cell and monocyte activation, reported in this disease (36) , reflects the costimulatory activity of sCD23 described in vitro. In addition, the activated mononuclear cells may contribute to increased CD23 expression inasmuch as activated monocytes readily express CD23 (14) and activated T cells are potent inducers of CD23 on B cells (37) . Finally, af~nity-purified native sCD23 was reported to induce monophasic fever in rabbits, further supporting the present in vitro data that sCD23 triggers the release of proinflammatory mediators (38) .
IFN-qr and TNF-c~ are two critical molecules that play a central role in the macrophage-mediated host defense against intracellular pathogens (39) . In addition, IFN-3~ is important in the regulation of physiological processes including Thl development and Ig-class switch (40) . Therefore, the ability of sCD23 to enhance IFN-'y and to trigger TNF-o~ production underlines its potential role in the control of the immune response.
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